Use of combination antiretroviral therapy (cART) and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) with or without rituximab for treatment of diffuse large B-cell lymphoma (DLBCL) in HIV substantially increases response rates but may also increase toxicity, possibly due to antiretroviral– antineoplastic drug interactions. The objective of this study was to evaluate the frequency of complete remission (CR) of DLBCL in patients treated with CHOP while receiving a protease inhibitor (PI) versus a non-PI-based cART.
Methods
A retrospective multicentre pilot study was conducted in HIV-infected patients on cART treated for DLBCL with CHOP between 2002–2010 in three academic hospitals.
Results
A total of 34 patients were included with 65% and 35% of patients receiving a PI and non-PI-based cART, respectively. Baseline characteristics between groups were similar; overall 85% were male, median age was 43 years, 50% had an International Prognostic Index (IPI) of 2–3 and median CD4+ T-cell count was 225 cells/mm3. CR was achieved in 77% and 58% of patients in the PI and non-PI groups, respectively (P=0.21), with 65% and 63% of patients achieving 2-year overall survival (P=1.00). A multivariate analysis showed that lower IPI score alone was significantly associated with higher CR rates (P=0.05). Toxicity was similar between both groups.
Conclusions
Similar efficacy and toxicity of CHOP was observed in patients receiving a PI and non-PI-based cART.
References
1.
ShielsM.S., PfeifferR.M., GailM.H.Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst2011; 103: 753–762.
2.
FranceschiS., LiseM., CliffordG.M.Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer2010; 103: 416–422.
3.
EngelsE.A., BiggarR.J., HallH.I.Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer2008; 123: 187–194.
4.
LanoyE., SpanoJ.P., BonnetF.The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer2011; 129: 467–475.
5.
RiberaJ.M., OriolA., MorgadesM.Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol2008; 140: 411–419.
6.
BouéF., GabarreJ., GisselbrechtC.Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol2006; 24: 4123–4128.
7.
KaplanL.D., LeeJ.Y., AmbinderR.F.Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood2005; 106: 1538–1543.
DiamondC., TaylorT.H., ImT., Anton-CulverH.Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma2006; 47: 1822–1829.
10.
NavarroJ.T., RiberaJ.M., OriolA.Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk Lymphoma2002; 43: 1837–1842.
11.
WeissR., MitrouP., ArastehK.Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival–results of the German Multicenter Trial. Cancer2006; 106: 1560–1568.
12.
NavarroJ.T., LloverasN., RiberaJ.M.The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica2005; 90: 704–706.
13.
MakinsonA., MartelliN., PeyriereH.Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol2007; 78: 358–360.
14.
VaccherE., SpinaM., di GennaroG.Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer2001; 91: 155–163.
KotbR., VincentI., DulioustA.Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol2006; 76: 269–271.
17.
RatnerL., LeeJ., TangS.Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol2001; 19: 2171–2178.
18.
AntoniouT., TsengA.L.Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet2005; 44: 111–145.
19.
AntoniouT., TsengA.Potential interactions between antineoplastics and antiretrovirals. In TsengA., FoisyM., editors. Handbook of HIV drug therapy. Toronto General Hospital: Toronto2013; pp. 320–357.
20.
ToffoliG., CoronaG., CattarossiG.Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol2004; 15: 1805–1809.
MounierN., KatlamaC., CostagliolaD., ChichmanianR.M., SpanoJ P.Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol2009; 72: 10–20.
23.
LeveyA.S., CoreshJ., GreeneT.Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem2007; 53: 766–772.
24.
ChesonB.D., HorningS.J., CoifferB.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol1999; 17: 1244–1253.
The International Non-Hodgkin's Lymphoma Prognostic Factors Project.A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med1993; 329: 987–994.
27.
CastilloJ.J., EcheniqueI.A.Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol2012; 87: 330–333.
28.
WyenC., JensenB., HentrichM.Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS2012; 26: 457–464.
29.
HaiounC., SalarA., PettengellR.Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ±rituximab chemotherapy: results from an observational study. Leuk Lymphoma2011; 52: 796–803.
